Casilda Balmaceda, MD
Neurology · New York, NYNPI 1093751919
Payments from drug & device makers
Across 1,532 payments — averaging $98.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$69K
- AbbVie$26K
- Biohaven Pharmaceuticals, Inc.$16K
- Biohaven Pharmaceutical Holding Company Ltd.$10K
- Eli Lilly$4K
- Abbott$4K
- plus $24K from 54 others
Across 1 payment — averaging $9565.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$10K
What the payments were for
- Consulting fees$2,3452%
- Speaking & faculty fees$108,89674%
- Travel & lodging$5,4554%
- Food & beverage$30,99621%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$68,495
- NURTEC ODT$25,440
- UBRELVY$21,009
- CYMBALTA$3,000
- INFINITY$1,953
- NOURIANZ$1,429
- MOVANTIK$1,040
- QULIPTA$375
- APOKYN$323
- Infinity DBS Pulse Generators$241
- GENERAL DBS$134
- Symbravo$125
- NONE$120
- VRAYLAR$115
How this compares
$151,367 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 704 | $1,082,324 |
| UbrelvyUbrogepant | 308 | $357,485 |
| RexultiBrexpiprazole | 205 | $338,745 |
| ApokynApomorphine Hcl | 14 | $309,653 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $261,343 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $204,095 |
| Diclofenac Sodium | 3,511 | $157,943 |
| LinzessLinaclotide | 253 | $130,991 |
| Aimovig AutoinjectorErenumab-Aooe | 162 | $123,422 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $108,179 |
| MovantikNaloxegol Oxalate | 163 | $63,980 |
| Lidocaine | 354 | $51,930 |
| RytaryCarbidopa/Levodopa | 96 | $48,128 |
| QuliptaAtogepant | 45 | $46,119 |
| NuedextaDextromethorphan Hbr/Quinidine | 35 | $45,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $996 | $1,082,324704 claims |
| AbbVieUbrelvy, Linzess, Qulipta, Vraylar | $25,979 | $575,690630 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,085 | $338,745205 claims |
| CSL BehringPrivigen | $79 | $261,34314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $158 | $204,09512 claims |
| Redhill Biopharma Inc.Movantik | $1,065 | $63,980163 claims |
| Amneal Pharmaceuticals LLCRytary | $2,257 | $48,12896 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $140 | $45,31635 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $541 | $43,430101 claims |
| UCB, Inc.Neupro | $1,375 | $22,65727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Sheng-Han KuoNew York$3.2M
- Stephen KriegerNew York$3.1M
- Thomas KaleyNew York$2.9M
- Aaron MillerNew York$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.